First description of azole-resistant Aspergillus fumigatus due to TR46/Y121F/T289A mutation in France

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 7, 2015, Pages 4331-4335

  Lavergne, Rose Anne ^a,b   Morio, Florent ^a,b   Favennec, Loïc ^c   Dominique, Stéphane ^d   Meis, Jacques F ^e,f   Gargala, Gilles ^c   Verweij, Paul E ^f   Le Papea, Patriqce ^a,b  

^a UNIVERSITÉ DE NANTES   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE ROUEN   (France)

^d ROUEN UNIVERSITY HOSPITAL   (France)

^e CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G ANTIBODY; ITRACONAZOLE; POSACONAZOLE; PYRROLE; VORICONAZOLE; ANTIINFECTIVE AGENT; CYTOCHROME P-450 CYP51A, ASPERGILLUS; CYTOCHROME P450; FUNGAL PROTEIN; FUNGUS ANTIBODY; PYRROLE DERIVATIVE;

ADULT; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS FUMIGATUS; CYP51A GENE; CYSTIC FIBROSIS; DISEASE EXACERBATION; EPSILOMETER TEST; FRANCE; FUNGICIDE RESISTANCE; FUNGUS CULTURE; GENE; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; MALE; PRIORITY JOURNAL; PROMOTER REGION; SHORT TANDEM REPEAT; YOUNG ADULT; ANTIFUNGAL RESISTANCE; ASPERGILLOSIS; CASE REPORT; DRUG EFFECTS; EUROPE; GENETICS; MICROBIOLOGY; MUTATION; RETROSPECTIVE STUDY;

ANTI-BACTERIAL AGENTS; ANTIBODIES, FUNGAL; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; AZOLES; CYSTIC FIBROSIS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, FUNGAL; EUROPE; FRANCE; FUNGAL PROTEINS; HUMANS; IMMUNOGLOBULIN E; ITRACONAZOLE; MALE; MUTATION; RETROSPECTIVE STUDIES; VORICONAZOLE; YOUNG ADULT;

EID: 84935879188     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00127-15     Document Type: Article

References (20)

1. Vermeulen E, Maertens J, Schoemans H, Lagrou K. 2012. Azole-resistant Aspergillus fumigatus due to TR46/Y121F/T289A mutation emerging in Belgium, July 2012. Euro Surveill 17(48):pii=20326. http: //www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20326.
2. van der Linden JW, Camps SM, Kampinga GA, Arends JP, Debets- Ossenkopp YJ, Haas PJ, Rijnders BJ, Kuijper EJ, van Tiel FH, Varga J, Karawajczyk A, Zoll J, Melchers WJ, Verweij PE. 2013. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis 57:513- 520. http://dx.doi.org/10.1093/cid/cit320.
3. Fischer J, van Koningsbruggen-Rietschel S, Rietschel E, Vehreschild MJ, Wisplinghoff H, Kronke M, Hamprecht A. 2014. Prevalence and molecular characterization of azole resistance in Aspergillus spp. isolates from German cystic fibrosis patients. J Antimicrob Chemother 69:1533-1536. http://dx.doi.org/10.1093/jac/dku009.
4. Astvad KM, Jensen RH, Hassan TM, Mathiasen EG, Thomsen GM, Pedersen UG, Christensen M, Hilberg O, Arendrup MC. 2014. First detection of TR46/Y121F/T289A and TR34/L98H alterations in Aspergillus fumigatus isolates from azole-naive patients in Denmark despite negative findings in the environment. Antimicrob Agents Chemother 58: 5096-5101. http://dx.doi.org/10.1128/AAC.02855-14.
5. Montesinos I, Dodemont M, Lagrou K, Jacobs F, Etienne I, Denis O. 2014. New case of azole-resistant Aspergillus fumigatus due to TR46/ Y121F/T289A mutation in Belgium. J Antimicrob Chemother 69:3439-3440. http://dx.doi.org/10.1093/jac/dku289.
6. Kuipers S, Bruggemann RJ, de Sevaux RG, Heesakkers JP, Melchers WJ, Mouton JW, Verweij PE. 2011. Failure of posaconazole therapy in a renal transplant patient with invasive aspergillosis due to Aspergillus fumigatus with attenuated susceptibility to posaconazole. Antimicrob Agents Chemother 55:3564-3566. http://dx.doi.org/10.1128/AAC.01544-10.
7. Steinmann J, Hamprecht A, Vehreschild MJ, Cornely OA, Buchheidt D, Spiess B, Koldehoff M, Buer J, Meis JF, Rath PM. 27 January 2015, posting date. Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany. J Antimicrob Chemother http://dx.doi.org/10.1093/jac/dku566.
8. Chowdhary A, Sharma C, Kathuria S, Hagen F, Meis JF. 2014. Azole-resistant Aspergillus fumigatus with the environmental TR46/Y121F/T289A mutation in India. J Antimicrob Chemother 69:555-557. http://dx.doi.org/10.1093/jac/dkt397.
9. Chowdhary A, Sharma C, van den Boom M, Yntema JB, Hagen F, Verweij PE, Meis JF. 2014. Multi-azole-resistant Aspergillus fumigatus in the environment in Tanzania. J Antimicrob Chemother 69:2979-2983. http://dx.doi.org/10.1093/jac/dku259.
10. Balajee SA, Gribskov JL, Hanley E, Nickle D, Marr KA. 2005. Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus. Eukaryot Cell 4:625-632. http://dx.doi.org/10.1128/EC.4.3.625-632.2005.
11. Rodriguez-Tudela JL, Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Monzon A, Cuenca-Estrella M. 2008. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob Agents Chemother 52:2468-2472. http://dx.doi.org/10.1128/AAC.00156-08.
12. European Committee on Antimicrobial Susceptibility Testing. 2014. Antifungal agents - breakpoint tables for interpretation of MICs, version 7.1. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/AF ST/Antifungal-breakpoints-v-7.0.pdf.
13. Morio F, Aubin GG, Danner-Boucher I, Haloun A, Sacchetto E, Garcia-Hermoso D, Bretagne S, Miegeville M, Le Pape P. 2012. High prevalence of triazole resistance in Aspergillus fumigatus, especially mediated by TR/ L98H, in a French cohort of patients with cystic fibrosis. J Antimicrob Chemother 67:1870-1873. http://dx.doi.org/10.1093/jac/dks160.
14. Alanio A, Sitterle E, Liance M, Farrugia C, Foulet F, Botterel F, Hicheri Y, Cordonnier C, Costa JM, Bretagne S. 2011. Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies. J Antimicrob Chemother 66: 371-374. http://dx.doi.org/10.1093/jac/dkq450.
15. Snelders E, Karawajczyk A, Schaftenaar G, Verweij PE, Melchers WJ. 2010. Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. Antimicrob Agents Chemother 54:2425-2430. http://dx.doi.org/10.1128/AAC.01599-09.
16. de Valk HA, Meis JF, Curfs IM, Muehlethaler K, Mouton JW, Klaassen CH. 2005. Use of a novel panel of nine short tandem repeats for exact and high-resolution fingerprinting of Aspergillus fumigatus isolates. J Clin Microbiol 43:4112- 4120. http://dx.doi.org/10.1128/JCM.43.8.4112-4120.2005.
17. Snelders E, Huis In 't Veld RA, Rijs AJ, Kema GH, Melchers WJ, Verweij PE. 2009. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol 75:4053-4057. http://dx.doi.org/10.1128/AEM.00231-09.
18. European Centre for Disease Prevention and Control. 2013. Technical report. Risk assessment on the impact of environmental usage of triazoles on the development and spread of resistance to medical triazoles in Aspergillus species. European Centre for Disease Prevention and Control, Solna, Sweden. http://dx.doi.org/10.2900/76274.
19. Vermeulen E, Lagrou K, Verweij PE. 2013. Azole resistance in Aspergillus fumigatus: a growing public health concern. Curr Opin Infect Dis 26:493-500. http://dx.doi.org/10.1097/QCO.0000000000000005.
20. Chowdhary A, Kathuria S, Xu J, Meis JF. 2013. Emergence of azole-resistant Aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health. PLoS Pathog 9:e1003633. http://dx.doi.org/10.1371/journal.ppat.1003633.